University of Florida

Environmental Health & Safety

Skip to main Content   Search   Main Navigation   Quick Links   Resources   Website   Social   Address   What is this view

Main Navigation

Quick Links

Home   Programs   Biological Safety   Vaccination Policy for Research Personnel Dosing Schedules and Immunogenicity Criteria – Required Vaccines

Dosing Schedules and Immunogenicity Criteria – Required Vaccines

Vaccine    Dosing Schedule    Immunogenicity Criteria   
Anthrax    Pre-exposure vaccination: 5 doses at 0, 4 weeks, 6 months, 12 months and 18 months.
Boosters are required annually to maintain immunity.     Individual is considered “protected” 3 weeks after the 3rd dose (given at 6 months).   
Hepatitis A     VAQTA®: 2 doses at 0 and 6-18 months
HAVRIX®: 2 doses at 0 and 6-12 months
TWINRIX® (combined HepA and HepB): 3 doses given at 0,1,6 months    In clinical trials, protective levels of antibodies seen in 94-100% of vaccinated persons ≥18 years 1 month after the 1st dose of any of the 3 HepA vaccines.   
Japanese Encephalitis     IXIARO®: 2 doses at 0 and 28 days
JE-VAX®: 3 doses at 0, 7 and 30 days    IXIARO®: considered protected 7 days after the 2nd dose
JE-VAX®: considered protected after the 3rd dose   
Meningiococcal     Laboratory workers routinely exposed to isolates of N. meningitidis should receive a single dose of MenACWY vaccine.    No immunogenicity data available.   
Polio     3 doses; two doses of IPV should be administered at intervals of 4-8 weeks; a 3rd doses should be administered 6-12 months after the 2nd dose.    

Individuals are considered protected after the complete 3-dose series. If 3 doses of IPV cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:

  • If >8 weeks are available before protection needed: administer 3 doses of IPV at least 4 weeks apart
  • If >8 but <4 weeks are available before protection is needed: administer 2 doses of IPV at least 4 weeks apart
  • If <4 weeks are available before protection is needed: a single dose of IPV is recommended.

Remaining doses should be administered later, at the recommended intervals, if person remains at increased risk for exposure to poliovirus.

Rabies     Primary vaccination: 3 doses given at 0, 7 and 21 (or 28) days   

The minimum acceptable antibody level a person must have to be considered protected is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test (RFFIT).

Serum testing requirements

  • Persons at continuous risk (including those working with rabies virus in a research laboratory or vaccine production facility) must have their serum tested every 6 months.
  • Persons at frequent risk (including those performing rabies diagnostic testing, veterinarians and veterinary staff and persons who frequently handle bats, regardless of location) must have their serum tested every 2 years.

For both groups- if the serum titer falls below the minimum acceptable antibody level (outlined above), a single booster of vaccine should be administered.

Vaccinia (smallpox)   

Recipients of standard potency vaccinia vaccine (Dryvax) receive controlled percutaneous doses (~2.5 x 105 PFU) of relatively low pathogenicity vaccinia virus.

Re-vaccination is required every 10 years.

Clinically, persons are considered fully protected after a successful response is demonstrated at the site of vaccination (vesiculo-papular response; scab resolved between Day 21 and Day 28 after vaccination).   

Ty21a (oral, live-attenuated):

Primary vaccination: 4 doses; one capsule every other day for a week (day 1, day 3, day 5 and day 7)
Boosters required every 5 years to maintain immunity.

Vi capsular polysaccharide:

Primary vaccination: 1 dose
Booster required every 2 years to maintain immunity.

Ty21a (oral, live-attenuated): individuals are considered protected one week after the final dose.

Vi capsular polysaccharide (inactivated): individuals are considered protected two weeks after receiving the vaccine.

Yellow Fever   

Primary vaccination: 1 dose

Booster vaccinations are required every 10 years to maintain immunity.

Most studies indicate that >99% of vaccinated persons develop YFV neutralizing antibodies by 28 days after vaccination.   

Primary vaccination: 1 dose

Booster vaccinations are required every 10 years to maintain immunity.

In clinical trials, the seroprotective rate for tetanus was 100% with the Tdap vaccine and 99.5% with the Td vaccine in adults aged 18-64 one month after vaccination.   
Influenza    A single dose of the seasonal influenza vaccine.    Dependent on yearly vaccine makeup, age group, and several other factors.   

Original February 17, 2014




Utility Links

New PI? Get EH&S Help

Social links


What is this view?

You are using a dynamic assistive view of the University of Florida site. It has all the same data and features of the original site but formatted just with assistive users in mind. It has links and content reorganized to aid assistive users and has controls at the bottom under assistive options that allow you to control key aspects such as font size and contrast colors etc.
This is not a separate text-only site, it's a dynamic view that uses unique technology from Usablenet to give assistive users better, more accessible access to the same content and features as all users that use the graphic view of the site.

Assistive Options

Top of page

Assistive Options

Open the original version of this page.

Usablenet Assistive is a Usablenet product. Usablenet Assistive Main Page.